This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 318-B:12-a · Treatment for Drug Abuse

Title: XXX: OCCUPATIONS AND PROFESSIONS
Chapter: 318-B · CONTROLLED DRUG ACT
Status: current
Official source linked: Yes

Official source Copy section link

318-B:12-a Treatment for Drug Abuse. – Any minor 12 years of age or older may voluntarily submit himself to treatment for drug dependency as defined in RSA 318-B:1, IX, or any problem related to the use of drugs at any municipal health department, state institution or facility, public or private hospital or clinic, any licensed physician or advanced practice registered nurse practicing within such nurse practitioner's specialty, or other accredited state or local social welfare agency, without the consent of a parent, guardian, or any other person charged with the care or custody of said minor. Such parent or legal guardian shall not be liable for the payment for any treatment rendered pursuant to this section. The treating facility, agency or individual shall keep records on the treatment given to minors as provided under this section in the usual and customary manner, but no reports or records or information contained therein shall be discoverable by the state in any criminal prosecution. No such reports or records shall be used for other than rehabilitation, research, or statistical and medical purposes, except upon the written consent of the person examined or treated. Nothing contained herein shall be construed to mean that any minor of sound mind is legally incapable of consenting to medical treatment provided that such minor is of sufficient maturity to understand the nature of such treatment and the consequences thereof. Source. 1971, 136:1. 1994, 333:24. 2009, 54:5, eff. July 21, 2009.

Copy link

Source note

Source. 1971, 136:1. 1994, 333:24. 2009, 54:5, eff. July 21, 2009.

Source history

1971, 136:1
1994, 333:24
2009, 54:5, eff. July 21, 2009

Related materials

Bill relationships

2026 HB1235 reference
es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s
2026 HB1235-FN reference
es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s
2026 HB1237 reference
owledging the receipt and understanding of the policy. XXII. Excluding the drugs described in 49 C.F.R. section 392.4 of the federal Motor Carrier regulations and outlined under RSA 318-B, the only drugs that may be transported are those legally prescribed by a licensed physician, in their original container, and in the possession of the person who is prescribed them. XXIII. A tow business whose driver
2026 HB1423 amend · effective 2027-01-01
ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de
2026 HB1423-FN amend · effective 2027-01-01
ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de
2026 HB1796 reference · effective 2027-01-01
arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t
2026 HB1796-FN reference · effective 2027-01-01
arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t
2026 HB186 reference
of Drugs. Any person who drives on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This
2026 HB186-FN-A amend
. 5 Model Drug Dealer Liability Act; Definition of Illegal Drug. Amend RSA 318-C:4, I to read as follows: I. "Illegal drug" means any drug which is a schedule I-IV drug under RSA 318-B, the possession, use, manufacture, sale, or transportation of which is not otherwise authorized by law. 6 New Chapter; Regulation of Cannabis. Amend RSA by inserting after chapter 318-E the following new chapter: CH
2026 HB194 reference · effective 2027-01-01
als under pharmacist supervision. A licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performan
2026 HB194-FN reference · effective 2027-01-01
licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performance
2026 SB465 amend · effective 2027-01-01
s a schedule III controlled drug. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c the following new section: 318-B:1-d Xylazine. I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of healt